Search results
Found 10583 matches for
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
University of Oxford, Department of Oncology, Athena SWAN Silver Application.pdf
This document is the Department of Oncology's application for an Athena SWAN silver level award.
University of Oxford, Department of Oncology, Athena SWAN Silver Application.pdf (2 MB)
University of Oxford, Department of Oncology 2020 Athena SWAN Action Plan.pdf
This document identifies the Department's key actions needed to realise its aims to further promote gender equality in higher education and research.
University of Oxford, Department of Oncology 2020 Athena SWAN Action Plan.pdf (373 KB)